April 27 - 30, 2024

at the Metro Toronto Convention Center, Toronto, ON, Canada

Booth #605

Visit us at Booth #605 and check out the additional activities below.

Jump to a section to learn more:

AATS Late Breaking Science

This year, AATS has put together a top-notch scientific program. Be sure to check out some of the key sessions we found interesting. Remember that you must be registered with the annual meeting to attend any sessions.


Sunday, April 28th | 8:12 AM

Novel Aortic Arch Hybrid Prosthesis in Acute DeBakey Type I Dissection- Early Results of the PERSEVERE Study

Presenter:

Shinichi Fukuhara, University of Michigan

Sunday, April 28th | 11:01 AM

Registry Results of Low-Dose Warfarin with a Novel Mechanical Aortic Valve Prosthesis: 5 Year Results

Presenter:

Marc Gerdisch, Franciscan Health

Ongoing Clinical Trials

Stop by our booth to learn more.


PERSEVERE Pivotal IDE Study

A ProspEctive, Single ARm, Multi-Center Clinical InveStigation to EValuatE the Safety and Effectiveness of AMDS* in the TREatment of Acute DeBakey Type I Dissection Pivotal IDE Study. AMDS is intended for aortic repair, aortic remodeling, and re-expansion of the intimal flap within the ascending aorta, aortic arch, and into the descending aorta for patients with acute DeBakey I aortic dissection undergoing open surgical repair within 0 to 14 days after diagnosis.

Triomphe Pivotal IDE Study

  Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUS) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Caution: AMDS and NEXUS are investigational devices. Limited by Federal (or United States) law to investigational use. All products and indications are not available/approved in all markets. Please contact your local Artivion representative for details.